Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Core LaboratoriesMEX:CLB 62 Debt-to-EBITDA is 7.43 as of Mar. 2026, which is 212% above its 10-year median of 2.38. GuruFocus rates MEX:CLB with a GF Score™ of 62/100 and a GF Value™ of MXN1,282.42. The stock has 3 warning signs investors should review. Among 705 Oil & Gas companies, Core Laboratories ranks worse than 57.3% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Core Laboratories's Debt-to-EBITDA or its related term are showing as below:
MEX:CLB'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.85 Med: 2.38 Max: 3.92
Current: 2.45
During the past 13 years, the highest Debt-to-EBITDA Ratio of Core Laboratories was 3.92. The lowest was -5.85. And the median was 2.38.
MEX:CLB's Debt-to-EBITDA is ranked worse than 57.3% of 705
companies
in the Oil & Gas industry
Industry Median: 2.01
vs MEX:CLB: 2.45
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Core Laboratories Debt-to-EBITDA Related Terms
Core Laboratories Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Core Laboratories's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:CLB vs EROK, OIS, NGS: Debt-to-EBITDA Comparison
For the Oil & Gas Equipment & Services subindustry, Core Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Core Laboratories Debt-to-EBITDA vs Oil & Gas Industry
For the Oil & Gas industry and Energy sector, Core Laboratories's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Core Laboratories's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Core Laboratories (MEX:CLB) has a Debt-to-EBITDA of 7.43 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Core Laboratories. This is 212% above median its historical median of 2.38. According to the industry distribution chart, Core Laboratories ranks #404 out of 705 companies in the Oil & Gas industry, placing it in the top 57.3%.
Is Core Laboratories' Debt-to-EBITDA too high?
Core Laboratories' current Debt-to-EBITDA of 7.43 is 212% above median its 10-year median of 2.38. The Oil & Gas industry median Debt-to-EBITDA is 2.01. Core Laboratories' value of 7.43 is 269.7% above this industry median. Based on the distribution chart, Core Laboratories ranks #404 out of 705 companies in the Oil & Gas industry, which is below the industry midpoint. Overall, Core Laboratories has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Core Laboratories' Debt-to-EBITDA compare to EROK and OIS?
According to the Oil & Gas industry distribution chart, Core Laboratories ranks #404 out of 705 companies for Debt-to-EBITDA. This places Core Laboratories in the lower half of its industry. The industry median Debt-to-EBITDA is 2.01. Core Laboratories' value of 7.43 is 269.7% above this benchmark. While the company's 10-year median is 2.38 vs. the industry median of 2.01, Core Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for an Oil & Gas company?
The median Debt-to-EBITDA among Oil & Gas companies is 2.01, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Core Laboratories's current Debt-to-EBITDA of 7.43 is 269.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Core Laboratories. For the Oil & Gas industry, the median Debt-to-EBITDA is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Core Laboratories's current Debt-to-EBITDA is 7.43, which is 212% above median its own 10-year median of 2.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Core Laboratories stock overvalued right now?
Core Laboratories (MEX:CLB) has a current Debt-to-EBITDA of 7.43. The stock's GF Value™ is MXN1,282.42, compared to a current price of MXN856.38 — trading 33.2% below its estimated fair value. The current Debt-to-EBITDA is 7.43, which is 212% above median its 10-year median of 2.38 and 269.7% above the Oil & Gas industry median of 2.01. Core Laboratories' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Core Laboratories (MEX:CLB), the current Debt-to-EBITDA is 7.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Core Laboratories (MEX:CLB) Overvalued in 2026?
Based on GuruFocus' analysis, Core Laboratories stock appears to be undervalued.
The current stock price of MXN856.38 is trading 33.2% below its estimated GF Value™ of MXN1,282.42.
Key valuation signals for MEX:CLB:
Debt-to-EBITDA: 7.43 (212% above median its 10-year median of 2.38)
GF Value™: MXN1,282.42 vs. price of MXN856.38 (33.2% below fair value)
Industry Position: 269.7% above the Oil & Gas median (#404 of 705)
No single metric tells the full story. See the MEX:CLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Core Laboratories Inc is a providers of proprietary and patented reservoir description and production enhancement services and products to the oil and gas industry, through client relationships. The company operates its business in two segments; Reservoir Description, and Production Enhancement. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services. The company generates majority of its revenue from Reservoir Description segment.
62GF Score
Get the complete analysis for MEX:CLB
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:CLB has been successfully added to your 
